Oculis Holding AG (OCS) Stock Score, Valuation & Financial Research

Oculis Holding AG is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for OCS

Oculis Holding AG does not currently have a complete Wall Street Score. The stored market price is USD 7.96. These figures are a research snapshot, not a buy or sell recommendation.

What Oculis Holding AG does

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Oculis Holding AG is a clinical-stage biopharmaceutical company that does not currently generate product revenue. Its business model focuses on the research and development of novel therapeutic candidates for ophthalmology and neuro-ophthalmology, relying on capital raises and strategic financing to fund its ongoing clinical trials and operational expenses.

Products and services

  • The company is developing a pipeline of clinical-stage candidates including OCS-01 (an eye drop for diabetic macular edema), Licaminlimab (an anti-TNFα biologic for dry eye disease), and Privosegtor (a neuroprotective agent for neuro-axonal diseases).

Brands and product families

  • OCS-01 — Proprietary eye drop candidate for diabetic macular edema using OPTIREACH technology. Source
  • Licaminlimab — Anti-TNFα biologic candidate for dry eye disease. Source
  • Privosegtor — Neuroprotective agent candidate for optic neuritis and other neuro-axonal diseases. Source

Customer types

Healthcare providers and patients participating in clinical trials.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct its clinical trials and manage data collection. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party contract manufacturing organizations for the production of its clinical trial drug supplies. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various established pharmaceutical and biotechnology firms developing treatments for ophthalmic and neuro-ophthalmic conditions. Source

Business strengths to evaluate

  • Late-stage clinical pipeline with proprietary technology platforms Source
  • Experienced management team and support from international healthcare investors Source

Business risks and research considerations

  • History of operating losses and dependence on future financing Source
  • Risks associated with clinical trial success, regulatory approval, and commercialization Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

OCS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.96
Market capitalization:
455.07M (currency not supplied)
Revenue:
USD 292.65K
Net income:
USD -95.93M
Free cash flow:
USD -75.28M
Cash:
USD 9.63K
Total debt:
USD 3.06M
EPS:
USD -1.69

What stands out

  • Free cash flow is USD -75.28M, negative for the stored period.
  • The balance sheet shows USD 9.63K of cash versus USD 3.06M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 3.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for OCS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can OCS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is OCS's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for OCS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of OCS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research OCS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.